4,722 Labcorp Holdings Inc. $LH Shares Purchased by Willis Investment Counsel

Key Points

• Willis Investment Counsel increased its Labcorp stake by 6.3%, purchasing 4,722 additional shares to hold 80,041 shares valued at approximately $24.7 million. Institutional investors collectively own 95.94% of the company.
• Labcorp reported quarterly EPS of $4.99, exceeding estimates of $4.78, while revenue rose 5.8% year over year to $3.73 billion. The company expects fiscal 2026 EPS of $18.10–$18.55.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $337.73, while shares recently traded at $322.57. Company insiders sold 8,593 shares worth about $2.7 million over the past 90 days.

Willis Investment Counsel grew its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 6.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,041 shares of the medical research company's stock after purchasing an additional 4,722 shares during the period. Willis Investment Counsel owned about 0.10% of Labcorp worth $24,661,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Allspring Global Investments Holdings LLC grew its position in Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company's stock valued at $607,241,000 after purchasing an additional 22,170 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Labcorp by 2.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company's stock worth $355,569,000 after buying an additional 28,584 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company's stock worth $218,901,000 after buying an additional 133,549 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of Labcorp in the 2nd quarter valued at about $168,222,000. Finally, Bessemer Group Inc. grew its holdings in shares of Labcorp by 47.3% in the 1st quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company's stock valued at $154,493,000 after acquiring an additional 185,847 shares in the last quarter. Institutional investors own 95.94% of the company's stock.

Labcorp Stock Performance

NYSE LH traded up $3.74 during trading on Tuesday, reaching $322.57. 163,499 shares of the company's stock were exchanged, compared to its average volume of 687,721. The business has a 50 day moving average price of $320.55 and a 200-day moving average price of $289.63. The stock has a market capitalization of $26.16 billion, a P/E ratio of 26.68, a PEG ratio of 1.81 and a beta of 0.87. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $341.80.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The company had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.71 billion. During the same period last year, the firm posted $4.35 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts forecast that Labcorp Holdings Inc. will post 18.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Barclays upped their target price on Labcorp from $320.00 to $330.00 and gave the stock an "equal weight" rating in a report on Friday, September 11th. UBS Group raised their price target on Labcorp from $361.00 to $380.00 and gave the company a "buy" rating in a research note on Friday, September 11th. Morgan Stanley boosted their price target on Labcorp from $308.00 to $338.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Bank of America upped their price objective on Labcorp from $300.00 to $320.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Finally, Mizuho set a $355.00 price objective on Labcorp in a report on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $337.73.

Insider Activity

In related news, CEO Adam H. Schechter sold 4,669 shares of Labcorp stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the sale, the chief executive officer owned 102,565 shares of the company's stock, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the company's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the transaction, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,593 shares of company stock valued at $2,733,295 over the last ninety days. 0.84% of the stock is currently owned by company insiders.

About Labcorp

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women's health testing, genetic testing, pathology services and other laboratory services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.